Discussion

This study evaluated early LVEF recovery among patients with PPCM treated with standard therapy with or without low-dose one-week bromocriptine. The principal finding was that both groups improved, and Group A had higher mean LVEF at one month. However, the finding must be interpreted as an association rather than proof of treatment effect because the study was observational, nonrandomized, small, and affected by important baseline imbalances.

The standard therapy issue is central to interpretation. In PPCM, background therapy must be adapted to pregnancy status, postpartum status, lactation, blood pressure, renal function, and thromboembolic risk. General HFrEF guidance supports multidrug therapy when safe and appropriate, but pregnancy and lactation can restrict or delay use of several drug classes [2,3]. Therefore, the term standard therapy in this study should be understood as pregnancy/postpartum-compatible therapy available during the study period, not as confirmation that all patients received contemporary full four-pillar HFrEF therapy. Because patient-level drug names, doses, duration, and adherence were not available, residual treatment differences between groups cannot be excluded.

The bromocriptine regimen also requires cautious interpretation. Group A received 2.5 mg once daily for one week. Published PPCM studies and protocols include both short-course and prolonged regimens, and the randomized German protocol specified anticoagulant therapy during the period of bromocriptine exposure [12,13]. The present study therefore evaluates a low cumulative dose strategy and cannot be generalized to prolonged bromocriptine protocols or to settings without careful thromboembolic risk assessment. The lack of patient-level anticoagulation data is a major limitation when assessing safety.

The direction and magnitude of the one-month LVEF difference may also be influenced by baseline differences. Group A had a wider gestational-age distribution, included patients presenting before 25 weeks of gestation, had a lower mean BMI, and had more abnormal electrocardiographic and chest radiographic findings at baseline. Group B had more recorded cases of hypothyroidism, higher TSH values, and more liver function test abnormalities. These imbalances may reflect different disease phenotypes, hemodynamic load, timing of diagnosis, nutritional status, or comorbidity burden. Without multivariable adjustment or stratified analyses, it is not possible to determine how much of the observed one-month LVEF difference was related to bromocriptine rather than baseline patient characteristics.

The discharge LVEF comparison illustrates the limitations of relying only on p-values in this small cohort. Although the categorical difference in LVEF below 45% at discharge appeared clinically relevant, the p-value was not statistically significant, and the confidence interval for the mean discharge LVEF difference crossed zero. This study was not adequately powered to exclude a clinically meaningful difference at discharge, and the one-month result should be viewed in the context of multiple unadjusted comparisons.

Neonatal outcomes require particularly cautious interpretation. Group A delivered at a lower gestational age and had lower birth weight, which are strong determinants of neonatal condition independent of bromocriptine. However, the uniform values in Group B, together with the between-group differences in gestational age at delivery and birth weight, require cautious interpretation. Therefore, the observed Apgar differences were not used to infer treatment-related neonatal benefit or harm.

Breastfeeding is another clinically important outcome. Bromocriptine suppresses lactation, and this has implications for maternal counseling, infant feeding, patient preference, and ethical consent. The present dataset did not capture breastfeeding intention, lactation counseling, alternative feeding plans, or infant feeding outcomes. This omission limits assessment of maternal-infant consequences of the intervention.

The present findings are consistent with the broader hypothesis that prolactin inhibition may be associated with improved ventricular recovery in PPCM, but they are less definitive than randomized or protocolized studies [10-15]. Echocardiographic assessment followed published chamber quantification recommendations [17], and earlier consensus documents and reviews support the diagnostic framework used for PPCM [18,19]. Observational studies from the United States and global systematic reviews have emphasized broad heterogeneity in clinical presentation and recovery [20-22], and population-based data support an association between hypertensive disorders and PPCM [23]. Additional pooled analyses of bromocriptine have suggested possible short-term improvement in LVEF, but the certainty of evidence remains limited [24]. These external data reinforce the need to account for phenotype and baseline risk before attributing recovery differences to a single drug.

Safety considerations remain important. Bromocriptine has been used for lactation suppression and prolactin-mediated conditions, but thrombotic and cardiovascular complications have been reported, particularly in the postpartum setting [25,26]. Historical descriptions and long-term outcome analyses show that PPCM recovery and prognosis often evolve over months to years rather than over one month [27,28]. Biomarker studies suggest that troponin and other markers may help identify persistent dysfunction in selected patients, but the present study did not demonstrate significant baseline troponin differences between groups [29].

This study has several strengths, including prospective enrollment from a tertiary care setting, direct comparison of two treatment strategies, and serial LVEF assessment. The limitations are substantial: nonrandomized treatment allocation, no documented allocation concealment or blinding, no a priori sample size calculation, small sample size, single-center design, one-month follow-up, lack of multivariable adjustment, multiple unadjusted comparisons, incomplete patient-level documentation of heart failure medications and anticoagulation, missing prolactin data. Additional limitations included incomplete lactation and breastfeeding data, broader-than-classical gestational inclusion, baseline imbalances in gestational age and body mass index, and the uniform Apgar score distribution in Group B, which limits interpretation despite source-record verification. These limitations substantially restrict causal inference and should be addressed in future studies.